Prospective study of type-2 diabetes mellitus and risk of primary open-angle glaucoma
Thus, when Rogers walked into the Iowa eye clinic during the summer of 1986 with his legal pad, the doctors took one look and realized they had stumbled upon the genetic equivalent of a winning lottery ticket: The family had enough living members with primary open-angle glaucoma
to allow an intensive hunt for the flawed gene.
Phase 2 dose-response study: Ocular Hypotensive Dose-response Efficacy and Safety of the Rho Kinase Inhibitor, K-115, in Patients with Primary Open-angle Glaucoma
and Ocular Hypertension (E-Poster Presentation)(*)
Food and Drug Administration (FDA) for the lowering of intraocular pressure (IOP) in primary open-angle Glaucoma
and Ocular Hypertension patients intolerant of or insufficiently responsive to other IOP-lowering medications.
Merck submitted an NDA to support the proposed use of SAFLUTAN for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma
or ocular hypertension.
Scientists at deCODE genetics and academic colleagues from Iceland, China, Sweden, the UK and Australia today report the discovery of the most important single-letter variation (SNP) in the sequence of the human genome yet associated with risk of primary open-angle glaucoma
Variations in primary open-angle glaucoma
prevalence by age, gender, and race: a Bayesian metaanalysis.
SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2 for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma
and ocular hypertension.
The First Preservative-Free Prostaglandin Eye Drop for the Treatment of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma
and Ocular Hypertension
The randomized, double-masked study enrolled 215 patients with primary open-angle glaucoma
or ocular hypertension, in one or both eyes.
The Phase 1/2 single ascending dose study, involving 84 subjects with primary open-angle glaucoma
or ocular hypertension, was designed to evaluate the safety, tolerability, and efficacy of INO-8875 administered topically to the eye.
This study is a phase II, randomized, masked, parallel-group study of safety and preliminary efficacy of a punctal plug drug delivery system involving up to 60 patients with primary open-angle glaucoma
or ocular hypertension.